J Pathol Transl Med.  2017 Jul;51(4):441-443. 10.4132/jptm.2016.10.18.

Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

• Park HK
• Seo Y
• Choi YL
• Ahn MJ
• Han J

• KMID: 2392587
• DOI: http://doi.org/10.4132/jptm.2016.10.18

Abstract

No abstract available.

MeSH Terms

Adenocarcinoma*
Carcinoma, Squamous Cell*
Epidermal Growth Factor*
Epithelial Cells*
Lung*
Receptor, Epidermal Growth Factor*
Epidermal Growth Factor
Receptor, Epidermal Growth Factor

Figure

• 

  Fig. 1. Squamous metastasis from lung adenocarcinoma. Initial lobectomy specimen (A–E) and punch biopsy specimen of the scalp (F–J). (A–C) The well-demarcated adenocarcinoma with solid and acinar growth patterns was found in the lobectomy specimen. The tumor shows thyroid transcription factor 1 immunoreactivity (D) and no p63 immunoreactivity (E). Punch biopsy specimen of the telangiectatic nodule on scalp (F) shows a tumorous lesion at the deep dermis (G). (H) This tumor shows a squamoid appearance with a sheet-like growth pattern. The tumor shows no TTF-1 immunoreactivity (I) and diffuse p63 immunoreactivity (J). EGFR, epidermal growth factor receptor.

Reference

1. Stewart EL, Tan SZ, Liu G, Tsao MS. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Transl Lung Cancer Res. 2015; 4:67–81.

2. Choi CM, Lee JC. Mechanisms of acquired resistance to epidermal growth factor receptor inhibitors and overcoming strategies in lung cancer. J Lung Cancer. 2012; 11:59–65.

3. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013; 19:2240–7.

4. Jukna A, Montanari G, Mengoli MC, et al. Squamous cell carcinoma “transformation” concurrent with secondary T790M mutation in resistant EGFR-mutated adenocarcinomas. J Thorac Oncol. 2016; 11:e49–51.

5. Kuiper JL, Ronden MI, Becker A, et al. Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor. J Clin Pathol. 2015; 68:320–1.

6. Levin PA, Mayer M, Hoskin S, Sailors J, Oliver DH, Gerber DE. Histologic transformation from adenocarcinoma to squamous cell carcinoma as a mechanism of resistance to EGFR inhibition. J Thorac Oncol. 2015; 10:e86–8.

7. Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015; 47:127–41.

8. Cagle PT, Chirieac LR. Advances in treatment of lung cancer with targeted therapy. Arch Pathol Lab Med. 2012; 136:504–9.

9. Ahn S, Hwang SH, Han J, et al. Transformation to small cell lung cancer of pulmonary adenocarcinoma: clinicopathologic analysis of six cases. J Pathol Transl Med. 2016; 50:258–63.